welcome to DuchenneXchange
- a positively charged Duchenne muscular dystrophy community.- join today!
- login
FDA paves way for clinical trials of Sarepta’s Duchenne MD therapy SRP-5051
The U.S. Food and Drug Administration has taken a step that will allow Sarepta Therapeutics to start clinical trials of its Duchenne muscular dystrophy therapy SRP-5051.
That move was accepting the company’s Investigational New Drug application for SRP-5051. The therapy, known as a peptide phosphorodiamidate morpholino oligomer, is designed to treat those whose Duchenne MD stems from the exon 51 genetic mutation. They constitute the largest group of DMD patients — about 13 percent.
Genes are made up of dozens of components known as exons. A missing exon can lead to a gene mutation that generates a faulty protein, causing a disease.
rareRelated
-
An open-label extension study for patients with Duchenne muscular dystrophy who participated in studies of SRP-5051The purpose of this extension study is t...
-
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of a Single Dose of SRP-5051 in Patients With Duc...The purpose of this study is to evaluate...
-
Wave Life Sciences Announces Positive Phase 1 Results for WVE-210201 in Duchenne Muscular Dystrophy (DMD)WVE-210201 safety and tolerability profi...
-
Results at 96 Weeks of a Phase IIb Extension Study of the Exon-Skipping Drug Eteplirsen in Patients with Duchenne Mu...Objective: The objective of this study ...
-
BioMarin snags cash as Sarepta skips Duchenne patent battleSarepta Therapeutics Inc. agreed to pay...
-
Wave Life Sciences Receives US Orphan Drug and Rare Pediatric Disease Designations for WVE-210201Wave Life Sciences Ltd., a biotechnology...
-
Dublin boy paves the way for new muscle disease treatmentA Dublin boy has become a pioneer in how...